July 14, 2008 - Allergan, Inc.'s wholly-owned subsidiary, Allergan Sales, LLC, and QLT USA, Inc., a wholly-owned subsidiary of QLT Inc. (NASDAQ:QLTI) (TSX:QLT) today announced the completion of Allergan's acquisition of QLT's Aczone(R) (dapsone) Gel 5% product, a topical treatment for acne vulgaris.
"We are pleased with the opportunity to grow our franchise in medical dermatology where there is a continuous need for new treatment options and strong growth potential," said David E.I. Pyott, Allergan's Chairman of the Board and Chief Executive Officer. "Building upon our more than 10 years of success with TAZORAC(R) (tazarotene), we will now offer dermatologists the only acne treatment with dapsone in a topical formulation to provide to their patients in North America."
The details can be read here.
No comments:
Post a Comment